Opinion|Videos|November 18, 2026

Interpreting MRD-Negative Responses in Relapsed/Refractory Multiple Myeloma

The faculty discuss the clinical significance of MRD-negative complete responses observed in the EXCALIBER-RRMM study of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma.

Episodes in this series

The faculty discuss the clinical significance of MRD-negative complete responses observed in the EXCALIBER-RRMM study of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. The panel considers the difference in MRD-negative CR rates between the investigational regimen and the comparator, discussing how response depth may inform the interpretation of clinical activity. Faculty emphasize that MRD negativity is associated with improved outcomes, while acknowledging the need for longer follow-up to determine whether the observed responses translate into durable MRD negativity and improved progression-free survival. The discussion also explores how clinicians should assess whether a new regimen offers sufficient benefit within an increasingly broad treatment landscape that includes CAR T-cell therapies and bispecific antibodies. Panelists consider the value of having treatment options with different mechanisms of action and the importance of sequencing therapies to maximize benefit over the course of the disease. They also highlight that EXCALIBER-RRMM primarily studied patients with one or two prior lines of therapy and limited prior anti-CD38 exposure, leaving questions about how these findings apply to more heavily pretreated populations.


Related to this article